Overvægt kliniske forsøg i Michigan
19 studier for Overvægt søger deltagere på steder i Michigan.
Byer i Michigan
Officiel studietekst (engelsk)
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Profound Research, Farmington Hills
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 28. sep. 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Northern Pines Hlth Ctr, PC, Buckley
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07720271A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Great Lakes Research Group, Inc., Bay City
- Great Lakes Research Institute, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Aa Mrc Llc, Flint
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Helen Devos Childrens' Hospital - PIN, Grand Rapids
RekruttererFase 3
Alder 6 til 17 · Alle køn · Opdateret 24. sep. 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Great Lakes Research Institute, Southfield
- Revive Research Institute, Inc., Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Farmington Hills
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Revive Research Institute, Inc., Southfield
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07369011A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 22. sep. 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Southfield
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743450A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 8. sep. 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- David Fivenson, MD, PLC, Ann Arbor
- The Derm Institute of West Michigan, Caledonia
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Farmington Hills
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Headlands Research - Detroit, Southfield
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 27. aug. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Troy
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arcturus Healthcare, PLC., Troy
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Ann Arbor
RekruttererFase 3
Alder 18 til 79 · Alle køn · Opdateret 10. aug. 2026 · NCT07654361Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.